London-based health tech startup specializing in AI-driven supplements by leveraging blood biomarker data, Bioniq, has secured $15 million in an oversubscribed series B funding round to expand its global market share and continue disrupting the dietary supplements market. Co-founded in 2019 by Vadim Fedotov, and Konstantin Karuzin, Bionic is currently valued at $75 million. The Bioniq will use the new capital to expand its global market share and disrupt the one-size-fits-all dietary supplement market.
read more..